Canton Strategic Holdings (CNTN) Cash from Financing Activities (2021 - 2026)
Canton Strategic Holdings (CNTN) posted Cash from Financing Activities of $87.0 million for Q1 2026, down 10.76% on a QoQ basis from $97.4 million in Q4 2025, and up 42200.79% year-over-year from N/an in Q1 2025.
Canton Strategic Holdings (CNTN) Cash from Financing Activities (2021 - 2026) Analysis & Trends
Canton Strategic Holdings' Cash from Financing Activities history runs 6 years deep, the most recent figure standing at $87.0 million for Q1 2026.
- Quarterly Cash from Financing Activities rose 42200.79% year-over-year to $87.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $193.9 million (up 5579.56% YoY) and the FY2025 annual result came in at $107.2 million, up 2939.54% from the prior year.
- Cash from Financing Activities was $87.0 million for Q1 2026 at Canton Strategic Holdings, down from $97.4 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $97.4 million in Q4 2025 and bottomed at -$338585.0 in Q3 2022.
- A 5-year average of $13.1 million and a median of $1.6 million in 2024 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities plunged 485.1% — and 2026, when it surged 42200.79%.
- Canton Strategic Holdings' Cash from Financing Activities stood at -$193457.0 in 2022, then jumped by 5094.25% to $9.7 million in 2023, then plunged by 81.18% to $1.8 million in 2024, then surged by 5257.28% to $97.4 million in 2025, then dropped by 10.76% to $87.0 million in 2026.
- Business Quant data shows CNTN's Cash from Financing Activities at $87.0 million in Q1 2026, $97.4 million in Q4 2025, and $7.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Canton Strategic Holdings | 427.87 Mn | 427.87 Mn | - | 86.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 86.96 Mn |
| Mar 31, 2026 | 86.96 Mn |
| Dec 31, 2025 | 97.44 Mn |
| Dec 31, 2025 | 97.44 Mn |
| Sep 30, 2025 | 7.22 Mn |
| Sep 30, 2025 | 7.22 Mn |
| Jun 30, 2025 | 2.31 Mn |
| Jun 30, 2025 | 2.31 Mn |
| Mar 31, 2025 | 205,568.00 |
| Mar 31, 2025 | 205,568.00 |
| Dec 31, 2024 | 1.82 Mn |
| Dec 31, 2024 | 1.82 Mn |
| Sep 30, 2024 | -257,730.00 |
| Sep 30, 2024 | -257,730.00 |
| Jun 30, 2024 | 1.65 Mn |
| Jun 30, 2024 | 1.65 Mn |
| Mar 31, 2024 | 317,119.00 |
| Mar 31, 2024 | 317,119.00 |
| Dec 31, 2023 | 9.66 Mn |
| Dec 31, 2023 | 9.66 Mn |